2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100239
    ICI 153110 87164-90-7 98%
    ICI 153110 is an orally active phosphodiesterase inhibitor with both vasodilating and inotropic properties which is designed for the treatment of congestive cardiac failure.
    ICI 153110
  • HY-100245
    OM-189 55381-18-5 98%
    OM-189 is a selective synthetic thrombin inhibitor.
    OM-189
  • HY-100253
    TA-7552 104756-72-1 98%
    TA-7552 is a potent cholesterol-lowering agent.
    TA-7552
  • HY-100254
    TAK-024 186971-69-7 98%
    TAK-024 is a platelet inhibitor with IC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.
    TAK-024
  • HY-100258
    Y-9738 59399-41-6 98%
    Y-9738 is a hypolipidemic agent.
    Y-9738
  • HY-100295
    (4-Acetamidocyclohexyl) nitrate 137213-91-3 98%
    (4-Acetamidocyclohexyl) nitrate (BM121307) is a guanylate cyclase activator.
    (4-Acetamidocyclohexyl) nitrate
  • HY-100302
    FR183998 free base 239440-20-1 98.00%
    FR183998 free base is a potent Na+/H+-exchange inhibitor, with IC50s of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pHi change in rat lymphocytes, rat and human platelets, respectively.
    FR183998 free base
  • HY-100312
    (±)-WS75624B 188048-45-5 98%
    (±)-WS75624B is an endothelin converting enzyme (ECE) inhibitor with an IC50 of 0.03 μg/mL.
    (±)-WS75624B
  • HY-100322
    H100 643727-55-3 98%
    H100 is a Cl- transport inhibitor, with partial effects against both the NaK2Cl cotransporter and the Band 3 anion exchanger, but no effect against KCl cotransporter, in human erythrocytes.
    H100
  • HY-100607
    Landiolol 133242-30-5 98%
    Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.
    Landiolol
  • HY-100623
    Dofetilide N-oxide 144449-71-8 98%
    Dofetilide N-oxide (UK-116856) is a metabolite of Dofetilide. Dofetilide is a class III antiarrhythmic agent that blocks potassium channels.
    Dofetilide N-oxide
  • HY-100795
    Pirmenol 68252-19-7 98%
    Pirmenol is an orally active antiarrhythmic agent. Pirmenol inhibits IK.ACh (IC50: 0.1 μM) by blocking mAchR. Pirmenol can be used in the research of cardiovascular disease, such as atrial fibrillation.
    Pirmenol
  • HY-100796
    Guanoclor 5001-32-1 99.34%
    Guanoclor is an antihypertensive compound. Guanoclor is an adrenergic neurone-blocking agent, which also interferes with noradrenaline synthesis by inhibition of the enzyme dopamine beta-hydroxylase.
    Guanoclor
  • HY-100851
    LY-272015 159730-07-1 98%
    LY-272015 is an orally active, specific 5-HT2B receptor antagonist. LY-272015 completely inhibits the phosphorylation of ERK2 induced by 5-HT or BW723C86. LY-272015 is antihypertensive in Deoxycorticosterone Acetate (DOCA)-salt-hypertensive rats.
    LY-272015
  • HY-101045
    AT-112 139047-55-5 98%
    AT-112 is a ketotanserin analogue. AT-112 has hemodynamic effects. AT-112 significantly reduces portal vein branch blood flow and portal vein pressure. AT-112 can be used to study the pathogenesis of portal hypertension.
    AT-112
  • HY-101050
    Tropanserin 85181-40-4 99.92%
    Tropanserin is a serotoninergic active compound, as well as a 5HT3 receptor antagonist. Tropanserin modulates Cardio-respiratory reflex effects of an exogenous serotonin challenge.
    Tropanserin
  • HY-101061
    2-MPMDQ 149847-77-8 98%
    2-MPMDQ is a potent and selective α1-adrenoceptor (Ki=0.37 nM) antagonist over α2-adrenoceptor (Ki=1740 nM). 2-MPMDQ is potent anti-hypertensive agent and has the potential for hypertension research.
    2-MPMDQ
  • HY-10119S
    Vorapaxar-d5 98%
    Vorapaxar-d5 is deuterated labeled Vorapaxar (HY-10119). Vorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner.
    Vorapaxar-d5
  • HY-101345
    AH 11110A 179388-65-9 98%
    AH 11110A is an α1B-adrenoceptor antagonist, but it can't effectively distinguish between the different subtypes of alpha(1) adrenoceptors (A, B, and D), nor can it clearly differentiate between alpha(1) and alpha(2) adrenoceptors.
    AH 11110A
  • HY-101355
    CGP 20712 137888-49-4 98%
    CGP 20712 is a highly selective β1-adrenoceptor antagonist (Ki=0.3 nmol/L). CGP 20712’s primary mechanism of action is through competitively binding to β1-receptors, thereby blocking the positive chronotropic effects of adrenaline and noradrenaline.
    CGP 20712
Cat. No. Product Name / Synonyms Application Reactivity